The FDA approved Ryzumvi for the treatment of pharmacologically induced mydriasis produced by adrenergic agonists or parasympatholytic agents, according to a press release from Ocuphire Pharma and Viatris.
Ryzumvi (phentolamine ophthalmic solution 0.75%), formerly known as Nyxol, was evaluated in the MIRA clinical trial program, which included more than 600 participants. In the MIRA-2 and MIRA-3 phase 3 pivotal trials, 553 participants aged 12 to 80 years were given two drops in the study eye or one drop in the fellow eye of either Ryzumvi or placebo 1 hour after induced mydriasis.
In the two